Atrium Therapeutics, Inc. RNA
Set alert
8.55 USD +0.28 +3.39%
At close
8.58 +0.03 +0.35%
Pre-market · Nov 3, 6:20 AM ET
8.19 Day range 8.64
7.49 52-week range 16.77
- YTD
- -42.03%
- 1 year
- -42.03%
- Open
- 8.22
- Prev close
- 8.27
- Mkt cap
- 146.25M
- Vol
- 470.07K
- Avg vol
- 285.05K
- EPS
- -5.44
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 8.19
- High
- 8.64
- Forward P/E
- -3.67
- Beta
- 0.00
- Short ratio
- 0.00
- Inst. own
- 0.25%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 15.47
- 200-d avg
- 15.47
- 1y target
- 0.00
Analyst view
Consensus: none
Price target (mean) 0.00
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | 0.00 | 0.00 – 0.00 | 0.00 | 0.0% | 0 | 0.0% | 0 |
| Next quarter | 0.00 | 0.00 – 0.00 | 0.00 | 0.0% | 0 | 0.0% | 0 |
| Current year | 0.00 | 0.00 – 0.00 | 0.00 | 0.0% | 0 | 0.0% | 0 |
| Next year | 0.00 | 0.00 – 0.00 | 0.00 | 0.0% | 0 | 0.0% | 0 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 11, 2025 | Chardan Capital | Maintained | Neutral | Neutral |
| Oct 29, 2025 | TD Cowen | Downgrade | Buy | Hold |
| Oct 28, 2025 | Chardan Capital | Downgrade | Buy | Neutral |
| Oct 28, 2025 | RBC Capital | Downgrade | Outperform | Sector Perform |
| Oct 27, 2025 | Citigroup | Downgrade | Buy | Neutral |
| Oct 27, 2025 | Leerink Partners | Downgrade | Outperform | Market Perform |
| Oct 27, 2025 | Raymond James | Downgrade | Strong Buy | Market Perform |
| Oct 27, 2025 | Bernstein | Downgrade | Outperform | Market Perform |
| Oct 27, 2025 | Needham | Downgrade | Buy | Hold |
| Oct 27, 2025 | HC Wainwright & Co. | Downgrade | Buy | Neutral |
| Sep 22, 2025 | Evercore ISI Group | Maintained | Outperform | Outperform |
| Sep 17, 2025 | Roth Capital | Initiated | — | Buy |
| Sep 15, 2025 | B of A Securities | Maintained | Buy | Buy |
| Sep 12, 2025 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Sep 10, 2025 | Needham | Maintained | Buy | Buy |
| Sep 10, 2025 | Chardan Capital | Maintained | Buy | Buy |
| Aug 8, 2025 | Wells Fargo | Maintained | Overweight | Overweight |
| Aug 8, 2025 | Barclays | Maintained | Overweight | Overweight |
| Aug 8, 2025 | Chardan Capital | Maintained | Buy | Buy |
| Jun 27, 2025 | Cantor Fitzgerald | Reiterated | Overweight | Overweight |
| Jun 17, 2025 | Wolfe Research | Initiated | — | Outperform |
| Jun 11, 2025 | Raymond James | Initiated | — | Strong Buy |
| Jun 10, 2025 | Citigroup | Maintained | Buy | Buy |
| Jun 10, 2025 | Barclays | Maintained | Overweight | Overweight |
| Jun 9, 2025 | B of A Securities | Maintained | Buy | Buy |
| Jun 9, 2025 | Chardan Capital | Maintained | Buy | Buy |
| May 12, 2025 | HC Wainwright & Co. | Maintained | Buy | Buy |
| May 9, 2025 | Chardan Capital | Maintained | Buy | Buy |
| May 7, 2025 | Chardan Capital | Maintained | Buy | Buy |
| Apr 9, 2025 | Needham | Reiterated | Buy | Buy |